Predicting immunotherapy benefit in leiomyosarcoma through active chromatin cfDNA profiling
- DOI
- 10.1038/s41698-026-01451-9
- Published
- 2026-05-05
- Container
- npj Precision Oncology
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1038/s41698-026-01451-9,
title = {Predicting immunotherapy benefit in leiomyosarcoma through active chromatin cfDNA profiling},
author = {Carlos Diego Holanda Lopes and Hsin-Ta Wu and Katharine Dilger and Yue Wendy Zhang and Abdulazeez Salawu and Lee-Anne Stayner and Abha A. Gupta and Aaron R. Hansen and Anna Spreafico and Philippe L. Bedard and Maggie C. Louie and Lillian L. Siu and Albiruni R. Abdul Razak},
year = {2026},
journal = {npj Precision Oncology},
doi = {10.1038/s41698-026-01451-9},
url = {https://doi.org/10.1038/s41698-026-01451-9}
}RIS
TY - JOUR TI - Predicting immunotherapy benefit in leiomyosarcoma through active chromatin cfDNA profiling AU - Carlos Diego Holanda Lopes AU - Hsin-Ta Wu AU - Katharine Dilger AU - Yue Wendy Zhang AU - Abdulazeez Salawu AU - Lee-Anne Stayner AU - Abha A. Gupta AU - Aaron R. Hansen AU - Anna Spreafico AU - Philippe L. Bedard AU - Maggie C. Louie AU - Lillian L. Siu AU - Albiruni R. Abdul Razak PY - 2026 JO - npj Precision Oncology DO - 10.1038/s41698-026-01451-9 UR - https://doi.org/10.1038/s41698-026-01451-9 ER -
APA
Lopes, C. D. H., Wu, H., Dilger, K., Zhang, Y. W., Salawu, A., Stayner, L., Gupta, A. A., Hansen, A. R., Spreafico, A., Bedard, P. L., Louie, M. C., Siu, L. L., & Razak, A. R. A. (2026). Predicting immunotherapy benefit in leiomyosarcoma through active chromatin cfDNA profiling. npj Precision Oncology. https://doi.org/10.1038/s41698-026-01451-9
Source records
- crossref · retrieved 2026-09-26T13:51:08.555Z